G-protein-coupled receptor-30 (GPR30) shows estrogen-binding affinity and mediates non-genomic signaling of estrogen to regulate cell growth. We here showed for the first time, in contrast to the reported promoting action of GPR30 on the growth of breast and ovarian cancer cells, that activation of GPR30 by the receptor-specific, non-estrogenic ligand G-1 inhibited the growth of androgen-dependent and androgen-independent prostate cancer (PCa) cells in vitro and PC-3 xenografts in vivo. However, G-1 elicited no growth or histological changes in the prostates of intact mice and did not inhibit growth in quiescent BPH-1, an immortalized benign prostatic epithelial cell line. Treatment of PC-3 cells with G-1 induced cell-cycle arrest at the G 2 phase and reduced the expression of G 2 -checkpoint regulators (cyclin-A2, cyclin-B1, cdc25c, and cdc2) and phosphorylation of their common transcriptional regulator NF-YA in PC-3 cells. With extensive use of siRNA-knockdown experiments and the MEK inhibitor PD98059 in this study, we dissected the mechanism underlying G-1-induced inhibition of PC-3 cell growth, which was mediated through GPR30, followed by sustained activation of Erk1/2 and a c-jun/c-fos-dependent upregulation of p21, resulting in the arrest of PC-3 growth at the G 2 phase. The discovery of this signaling pathway lays the foundation for future development of GPR30-based therapies for PCa. Estrogens can trigger rapid signaling responses through plasma membrane-mediated intracellular signaling independent of nuclear translocation.
Estrogens can trigger rapid signaling responses through plasma membrane-mediated intracellular signaling independent of nuclear translocation. 1, 2 Previous studies showed that B5-10% of endogenous estrogen receptors [ERa/ERb] and their splice variants present at the plasma membrane are responsible for these responses. [1] [2] [3] [4] [5] Recently, an orphan G-protein-coupled receptor (GPR30) with high-affinity and low-capacity binding to estrogens was localized to both plasma membrane and the endoplasmic reticulum. Upon binding to ligand, GPR30 induces rapid but transient activation of extracellular signal-regulated kinase-1/2 (Erk1/2) to stimulate proliferation in ER-negative breast cancer cells, and in endometrial and ovarian cancer cells. [6] [7] [8] [9] [10] By contrast, normal and malignant bladder urothelial cells respond to GPR30 activation with reduction in cell proliferation. 11 These findings suggest dual roles for GPR30 in the regulation of cell growth, depending on cell type. It has been suggested that GPR30 functions as a membranous estrogen receptor to elicit physiological estrogenic responses in the targeted cells, 10 but contradictory data have challenged this idea. 4, 12 Thus, the biological significance of GPR30 remains unclear.
The identification of G-1 (1-[4-(6-bromobenzo [1, 3] dioxol-5yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone) as a GPR30-selective agonist 13 is a major advancement toward elucidating the biological significance of GPR30, especially in cells that express ERa and/or ERb. Activation of GPR30 by G-1 was found to stimulate proliferation in BG-1 ovarian cancer cells and SKBR3 breast cancer cells through induction of c-fos expression. 9 In BG-1 cells, expression of cyclin-D1, cyclin-E, and cyclin-A1 was also found to be upregulated by G-1. 9 In SKBR3 cells, 17b-estradiol (E2)-or phytoestrogen-mediated stimulation of cell proliferation was shown to be mediated through GPR30, as these responses were abrogated by a GPR30-antisense oligonucleotide. 9, 14 Similar findings were reported for ovarian, endometrial, and thyroid cancer cells in knockdown studies. [7] [8] [9] Collectively, these data show that G-1 is a useful investigative tool for studying GPR30-mediated signaling.
In this study, we showed the inhibitory role of GPR30 in the growth of prostate cancer (PCa) cells by investigating the effects of G-1 on an Erk1/2 kinase activation cascade that is causally linked to aberrant expression of early-response genes, upregulation of p21, and cell-cycle arrest at the G 2 phase in PCa cells. . Using a soft-agar assay, 15 G-1 was shown to inhibit anchorage-independent growth of PC-3 cells, which was blocked by the GPR30 siRNA (Figure 1c) . These data support a direct link between GPR30 and G-1-induced growth inhibition in PC-3 cells.
Similar to PC-3 and DU145 cells, androgen-dependent LNCaP cells also showed growth inhibition in response to G-1 treatment (Supplementary Figure S1) . Regarding non-malignant prostatic epithelial cells, G-1 treatment only induced growth inhibition in actively proliferating BPH-1 cells grown in charcoal-stripped fetal bovine serum but not in growthquiescent cells kept in serum-free medium (Supplementary Figure S2) . The data suggest that non-malignant prostatic epithelial cells in a growth-quiescent state such as one found in the normal prostate 16, 17 are not susceptible to G-1-induced growth inhibition.
To directly investigate the effect of G-1 on normal prostatic epithelial cells in vivo, we treated intact nude mice daily with G-1 at 4 mg/kg/day for 7 days. No significant difference was observed in total body weight, prostate weight, and histology of the G-1-treated mice when compared with that in vehicletreated controls (Supplementary Figure S3) . These findings indicate that normal prostatic epithelial cells in vivo are not responsive to G-1-treatment and G-1 has minimal toxicity in intact mice.
The PC-3 xenograft model was used to evaluate the effects of G-1 on PCa growth in vivo. Daily treatment with G-1 significantly suppressed the growth of the xenografts over the entire treatment period, as compared with vehicle treatment (Figure 1d ). There was no difference between the body weights (without tumor) of the vehicle-and the G-1-treated mice, further supporting that G-1 was minimally toxic in nude mice (Figure 1d, right panel) . Results of quantitative RT-PCR analysis of seven pairs of clinical PCa samples and their corresponding adjacent normal tissues showed a trend of slight reduction in GPR30 transcript levels in cancers (P ¼ 0.1288), similar to DNA microarray data found in Oncomine (Supplementary Figure S4) .
To rule out the involvement of ERa or ERb in the G-1-induced growth inhibition, PC-3 cells were treated with G-1 in the absence or presence of an ER antagonist. Treatment of PC-3 with 1 mM G-1 alone induced a significant reduction in cell growth (Figure 1e ). Co-treatment of PC-3 cells with G-1 and 1 mM of fulvestrant (an ERa and ERb antagonist) or an ER subtype antagonist (1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride (MPP dihydrochloride; an ERa antagonist) or 4-[2-phenyl-5,7-bis (trifluoromethyl)pyrazolo [1,5-a] pyrimidin-3-yl]phenol (PHTPP; an ERb antagonist)) was unable to reverse the G-1-induced growth inhibition, suggesting that the effect of G-1 is not mediated through one of these receptors. PC-3 cells were also treated with E2 (10 À9 -10 À6 M), and minimal or no inhibition of PC-3 cell growth was observed (data not shown), a finding similar to one of our previous reports. 18 E2 was also found to have no promoting or inhibitory effects on G-1-induced cell growth inhibition in PC-3 cells (Supplementary Figure S5) . Figure S8) .
To determine whether the G-1-treated PC-3 cells were arrested at the G 2 or the mitotic phase, we examined changes in the expression of a panel of cell-cycle-specific markers over time ( Figure 2b ). The two mitotic phase markers, phosphorylated Bcl-2 and MPM-2, either were not expressed or showed no significant change in expression levels over time ( Figure 2b ). In contrast, expression levels of G 2 -checkpoint regulators, including cyclin-B1, cyclin-dependent kinase-1 (cdc2), and its phosphorylated proteins, and cdc25c were significantly downregulated in PC-3 cells treated with G-1 over a 72-h period. In addition, the level of cyclin-A2, which functions in the transition from both G 1 to S and G 2 to the mitotic phase of the cell cycle, also decreased; however, expression of cyclin-E, which is involved in transition from G 1 to S, did not change. In agreement with changes in the protein level, expression of mRNAs of cyclin-B1, cdc2, cdc25C, and cyclin-A2, but not of cyclin-E, was also significantly downregulated ( Figure 2c ). Collectively, these data support the notion that G-1induces cell-cycle arrest at the G 2 phase in PC-3 cells. That nuclear factor-Y A-subunit (NF-YA) regulates the transcriptional expression of G 2 -checkpoint regulators, 19, 20 and G-1 reduced the phosphorylation of NF-YA, but did not change NF-YA protein level per se, in PC-3 cells (Figure 2d ), further supports cell cycle arrest at the G-2 phase.
G-1 induced a sustained GPR30-dependent phosphorylation and nuclear accumulation of Erk1/2. Treatment of PC-3 cells with 1 mM G-1 over a 3-day period induced a sustained increase in the level of phosphorylated Erk1/2 but did not change the level of total Erk1/2 protein ( Figure 3a , upper panels). The earliest time point at which Erk1/2 phosphorylation became noticeable is after 1 h of G-1 treatment (Figure 3a , lower panel). Such induced phosphorylation was also found in G-1-treated LNCaP cells (Supplementary Figure S9) . The G-1-induced phosphorylation of Erk1/2 in PC-3 cells was then shown to be mediated by GPR30, as transfection of a GPR30-siRNA into these cells abrogated the G-1 action (Figure 3b ).
Similar to a previous report, 21 in a temporal study, we observed a time-dependent increase in the nuclear localization of phosphorylated Erk1/2 in G-1-treated PC-3 cells that lasted for at least 24 h (Figure 3c) . In contrast, G-1-induced nuclear accumulation of phosphorylated Erk1/2 in MCF-7 cells peaked at 1 h after treatment and rapidly declined to undetectable levels by 24 h (Figure 3c) . Thus, PC-3 cells are capable of retaining phosphorylated Erk1/2 in their nuclei for a significantly longer duration than do MCF-7 cells.
We next asked whether Erk1/2 activation, rather than phosphoinositide-3-kinase, is the principal downstream mediator of G-1 action in PC-3 cells. PC-3 cells were treated with the MEK inhibitor PD98059 or the phosphoinositide-3-kinases inhibitor LY294002. Only the former inhibitor blocked the G-1-induced inhibition of cell growth (Figure 3d ), confirming our hypothesis that G-1's action in PC-3 cells is primarily mediated by Erk1/2 activation.
G-1 induced p21 expression to inhibit cell growth through GPR30-mediated signaling. Activation of GPR30 by G-1 markedly increased p21 expression at both the mRNA and protein levels in a dose-and time-dependent manner in PC-3 cells (Figure 4a ). The overexpression was completely abolished by GPR30-siRNA but not by a scramble siRNA control (Figure 4b ). G-1-induced p21 upregulation was also observed in LNCaP cells (Supplementary Figure S9) . Importantly, an siRNA-mediated p21 knockdown in PC-3 cells (Figure 4d , fourth panel) effectively abrogated the growthinhibitory action of G-1 on these cells (Figure 4c ). In line with this abrogation, the knockdown also prevented the G-1-induced downregulation of cyclin B1, cdc25c, and cdc2 expression in the cells (Figure 4d) . These findings establish G-1-induced p21 upregulation as a direct mediator of the growth-inhibitory response.
Obliteration of G-1-induced p21 upregulation by MEK inhibitor PD98059. Treatment with 1 mM G-1 for 48 h induced significant phosphorylation of Erk1/2 and upregulation of p21 expression in PC-3 cells. Pretreatment with 30 mM PD98059 obliterated the inductive effects of G-1, as this inhibitor completely abolished p21 upregulation and Erk1/2 phosphorylation in the cells (Figure 4e ). These findings suggested that phosphorylation of Erk1/2 is essential for upregulation of p21 expression in G-1-treated PC-3 cells. 
complex, which is composed of two early-response gene proteins, c-jun and c-fos. 22 Treatment with 1 mM G-1 for 24 h induced c-jun and c-fos expression at the mRNA and protein level as compared with that in controls (Figure 5a ). The expression of c-jun is regulated by a feed-forward mechanism. 23 Phosphorylation of c-jun activates its transcriptional ability, leading to induction of more c-jun expression. 24 We found that treatment with 1 mM G-1 for 24 h induced the phosphorylation of c-jun and c-fos, in which pretreatment with MEK inhibitor PD98059 before G-1 treatment significantly reduced the induction (Figure 5b ). These findings supported that activation of MEK by G-1 induced the early expression of c-jun and c-fos in PC-3 cells.
As phosphorylation of MSK1 and ATF1 has been shown to be an upstream regulator of c-jun expression, 25 we treated PC-3 cells with 1 mM G-1 for 24 h and observed marked induction of these two proteins in their phosphorylated form (Figure 5c ). Similarly, we found significant increase in phosphorylated Elk-1, an upstream regulator of c-fos, in G-1-treated PC-3 cells (Figure 5c ). These findings indicate that activation of GPR30 by G-1 can act on early-response genes c-jun and c-fos through their respective upstream regulators.
Involvement of c-jun and c-fos in the G-1-induced upregulation of p21. G-1 treatment induced c-jun and c-fos expression along with upregulation of p21 and downregulation of cyclin-B1 in PC-3 cells, as described above. siRNA knockdown of either c-jun or c-fos alone (Figure 6a ) blocked the G-1-induced cell growth inhibition (Figure 6b ). In addition, double siRNA knockdown of c-jun and c-fos completely reversed the inhibitory effect of G-1 on cell growth (Figure 6b ). Consistent with our hypothesis that induction of c-jun and c-fos is the downstream target of G-1-induced Erk1/2 activation in PC-3 cells, siRNA knockdown of c-jun or c-fos did not affect the phosphorylation of Erk1/2 by G-1 (Figure 6c) . However, the knockdowns abolished the upregulation of p21 and downregulation of cyclin-B1 in these cells (Figure 6c ), indicating that p21 and a G 2 -checkpoint regulator (cyclin-B1) are downstream of these earlyresponse genes. These findings indicate that upregulation of c-jun or c-fos is downstream from Erk1/2 activation but upstream from p21 upregulation.
Discussion
Here we report that activation of GPR30 by the receptorspecific, non-estrogenic ligand G-1 leads to growth inhibition of PCa cells (PC-3, DU145, and LNCaP) in culture and as xenografts (PC-3) in nude mice. This finding is in stark contrast to the growth-promoting action of G-1 mediated by GPR30 activation in breast, endometrial, ovarian, and thyroid cancer cell lines. [7] [8] [9] 14 Furthermore, we found G-1 to have little or no effects on mouse prostate (weight and histology) and on growth-quiescent immortalized benign prostatic epithelial cells in cultures. As depicted in Figure 7 , we propose a model illustrating the steps involved in the G-1-induced, GPR30-mediated growth-inhibitory cascade in PCa cells, which were empirically validated by a comprehensive series of siRNAknockdown experiments and the MEK inhibitor PD98059. In PC-3 cells, G-1, through GPR30 activation, caused prolonged activation and nuclear accumulation of Erk1/2. G-1 also activated the early-response genes c-jun and c-fos, leading to upregulation of p21, which in turn downregulated a number of key G 2 -checkpoint regulators and ultimately led to cell-cycle arrest at the G 2 phase in PC-3 cells.
Previous studies by us 18 and others 26 showed that both ICI 182,780 (ICI) and E2 inhibited PC-3 cell growth in a modest manner. As PC-3 expresses ERa and ERb, as well as GPR30, it is difficult to pinpoint which of the three receptors is responsible for mediating the growth-inhibitory action of the anti-estrogen/estrogen. However, E2 was shown to have a 15-fold higher affinity for ERa and ERb than for GPR30. 13 Thus, it is thought that the action of ICI/E2 is mediated largely through transactivation of the ERs rather than GPR30 in PC-3 cells. To study the specific effect of GPR30 in ER-positive PC-3 cells, we used G-1, which is a selective ligand for GPR30, in this study. G-1 has little to no affinity for the two ERs, 13 suggesting that inhibition of PC-3 cell growth is attributable primarily to activation of GPR30. This premise was confirmed by siRNA knockdown of GPR30, which effectively blocked the inhibitory effects of G-1 on PC-3 cell growth. Furthermore, G-1 is unlikely to act through ERs, as blockade of ER's action by specific antagonists (ICI, MPP dihydrochloride, PHTPP) did not alter the growth-inhibitory effects of G-1 on PC-3 cells.
The mode of action of G-1 and its interaction with GPR30 in PCa cells have not been studied previously. In the ERnegative SKBR3 breast cancer cell line, GPR30 mediates the E2-induced rapid activation of Erk1/2 (o0.5 h), leading to cell growth 9 and cell migration. 27 In this study, G-1 has also been shown to induce Erk1/2 activation in PC-3 cells, but the biological consequence was a profound inhibition of cell growth. Both Erk1/2 activation and cell growth inhibition were dependent on GPR30, as siRNA knockdown of the receptor effectively blocked these responses. In addition, G-1-induced Erk1/2 activation and cell growth inhibition were both suppressed by the MEK inhibitor PD98059, indicating that the kinase is the common upstream regulator. In human umbilical vein smooth-muscle cells, G-1 exerted a similar biological action by inducing Erk1/2 activation and cell growth inhibition. At this point we do not know why G-1 activation of GPR30 induces opposite effects on cell growth in different cell types, but these differences may be related to the duration of the nuclear occupancy of activated Erk1/2. Upon activation, the phosphorylated Erk1/2 translocates from the cytoplasm to the nucleus to phosphorylate their nuclear targets for transcriptional regulation. 21 It has been proposed that the signal duration of Erk1/2 activation could dictate a cell-fate decision, 29 with transient Erk1/2 activation leading to cell survival and proliferation and sustained activation with nuclear accumulation of activated Erk1/2 transmitting antiproliferative signals. [29] [30] [31] [32] A previous study reported that the differences between the cell growth responses of osteoclasts/osteocytes and osteoblasts to estrogens depend on the kinetics of Erk1/2 activation and the duration of nuclear accumulation of phosphorylated Erk1/2. 31 In this study, we showed that the G-1-induced Erk1/2 activation in PC-3 cells was rapid but unusually prolonged (X24 h) as compared with that induced in MCF-7 cells, which peaked at 1 h and disappeared by 24 h. Whether the signal duration of Erk1/2 activation is central to the PCa cell growth response to G-1 requires future studies to clarify the role of GPR30 in cell-fate determination.
The cell-cycle regulator p21 was originally thought to inhibit cell-cycle progression in the G 1 phase, but recent evidence indicates that it is also involved in G 2 /M arrest. 33, 34 Upregulation of p21 has been shown to associate with nuclear translocation of G 2 -checkpoint regulators. 35 An association between p21 induction and downregulation of cyclin-B and cdc25C has been linked to G 2 /M arrest. 36, 37 Here we report G-1-induced p21 upregulation and significant downregulation of several G 2 -specific checkpoint proteins. One mechanism by which p21 upregulation suppresses multiple G 2 -checkpoint regulators is by inhibiting the phosphorylation of the NF-YA, which binds to a common CCAAT motif in these proteins. 38, 39 Indeed, we observed significant reduction in NF-YA phosphorylation after G-1 treatment. Finally, we found siRNA knockdown of p21 to effectively block the G-1-induced inhibition of cell growth and reverse the downregulation of G 2 -checkpoint modulators. These findings provide credence for p21-mediation of the G-1-induced-cell cycle arrest at the G 2 phase in PC-3 cells.
We further investigated the mechanism underlying GPR30-mediated p21-induced growth inhibition in PC-3 cells. Kardassis et al. 40 showed that c-jun transactivated the p21 gene promoter. This finding prompted us to ascertain if the G-1-induced upregulation of p21 is caused by increased expression and/or activation of the early-response genes. We found that c-jun and c-fos were upregulated and activated in G-1-treated PC-3 cells. Furthermore, our study also showed that the transcriptional factors MSK1 and ATF1 that activate c-jun, as well as Elk-1 that activates c-fos, 25 were phosphorylated in G-1-treated cells. Knockdown of each of the early-response genes with small interfering RNA blocked p21 upregulation, cyclin-B downregulation, and growth inhibition induced by G-1 in PC-3 cells. Collectively, these data support the mediation of G-1induced p21 upregulation through activation of the early-response genes c-jun and c-fos in PC-3 cells.
Our data showed that GPR30 was expressed in variable but detectable levels in PCa tissues and cell lines, and G-1 induced cell growth inhibition in both androgen-responsive (e.g., LNCaP) and androgen-deprivation-resistant (e.g., PC-3) PCa cells in vitro and in vivo. The treatment was found to have minimal or no effects on normal prostatic epithelial cells in the mouse prostate. It also did not affect benign prostate epithelial cells (e.g., BPH-1) in a growth-quiescent state, which is the state most normal epithelial cells are in in vivo. 16, 17 Therefore, this agent may have the potential to be used alone or in combination with androgen-deprivation therapies as a first-line treatment regimen for advanced PCa, local or metastatic. The treatment is likely to pose little or no harmful effects on normal prostatic tissues in patients. Additionally, it may add efficacy when used in conjunction with standard chemotherapies for metastatic PCa.
In conclusion, we showed that treatment of PCa cells with G-1 induced growth inhibition in vitro and in vivo through activation of GPR30 and cell-cycle arrest at the G 2 phase. We further provided evidence supporting a novel G-1/GPR30-signaling pathway that involves protracted activation of Erk1/2 that is linked to a c-jun-and c-fos-mediated increase in p21 expression. The discovery of this signaling pathway opens up new opportunities for the development of GPR30-based therapies for PCa by using G-1 or its derivatives.
Materials and Methods Analysis by reverse transcription-PCR (RT-PCR).
Total RNA samples were reverse-transcribed using Moloney murine leukemia virus reverse transcriptase and random hexamer (Applied Biosystems, Foster City, CA, USA). Primer sequences are presented in Supplementary Table S1 . PCR reactions with SYBR Green PCR Master-Mix (Applied Biosystems) were monitored in real-time with iCYCLER (Bio-Rad Laboratories, Hercules, CA, USA). Cycle thresholds (C T ) of the genes of interest were compared with those of ribosomal protein-3 (RPS3) to determine relative expression levels. Relative fold changes between the expression of the genes of interest in treated and control samples were determined by the equation: fold change ¼ 2
, where 
